We are live on ! Find out more
LOGC

LogicBio Therapeutics, Inc. Common Stock
LOGC

Delisted

LOGC was delisted on the 15th of November, 2022.

Back to rankings

39 hedge funds and large institutions have $513K invested in LogicBio Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% less funds holding

Funds holding: 47 → 39 (-8)

44% less capital invested

Capital invested by funds: $917K → $513K (-$405K)

50% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 8

73% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 11

Holders
39
Holders Change
-8
Holders Change %
-17.02%
% of All Funds
0.67%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
8
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$73.7K
2
Citadel Advisors
Citadel Advisors
Florida
+$45.9K
3
VF
Virtu Financial
New York
+$32K
4
Prudential Financial
Prudential Financial
New Jersey
+$13.7K
5
Simplex Trading
Simplex Trading
Illinois
+$237

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$124K
2
Franklin Resources
Franklin Resources
California
-$109K
3
HCA
Harbor Capital Advisors
Illinois
-$85K
4
Renaissance Technologies
Renaissance Technologies
New York
-$54.2K
5
Jane Street
Jane Street
New York
-$18K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$136K +$73.7K +186,229 +59%
Renaissance Technologies
2
Renaissance Technologies
New York
$77K -$54.2K -136,922 -33%
BlackRock
3
BlackRock
New York
$47K -$1.39K -3,509 -2%
BBA
4
Baker Bros. Advisors
New York
$38K -$124K -312,373 -69%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$37K – – –
Citadel Advisors
6
Citadel Advisors
Florida
$32K +$45.9K +115,925 New
Prudential Financial
7
Prudential Financial
New Jersey
$27K +$13.7K +34,600 +54%
VF
8
Virtu Financial
New York
$22K +$32K +80,774 New
BCM
9
Bridgeway Capital Management
Texas
$15K -$6.33K -16,000 -23%
Acadian Asset Management
10
Acadian Asset Management
Massachusetts
$13K – – –
FT
11
Fiduciary Trust
Massachusetts
$13K – – –
IBOK
12
Independence Bank of Kentucky
Kentucky
$12K – – –
State Street
13
State Street
Massachusetts
$9K – – –
Northern Trust
14
Northern Trust
Illinois
$8K – – –
TYCC
15
Texas Yale Capital Corp
Florida
$5K – – –
SMH
16
Sanders Morris Harris
Texas
$4K – – –
UBS Group
17
UBS Group
Switzerland
$3K -$4.52K -11,428 -54%
TRCT
18
Tower Research Capital (TRC)
New York
$3K -$4.09K -10,328 -47%
Morgan Stanley
19
Morgan Stanley
New York
$3K – -1 -0%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$3K – – –
O
21
OrbiMed
New York
$2.31K – – –
Fidelity Investments
22
Fidelity Investments
Massachusetts
$1K -$20 -50 -1%
Barclays
23
Barclays
United Kingdom
$1K – – –
US Bancorp
24
US Bancorp
Minnesota
$1K – – –
FDCDDQ
25
Federation des caisses Desjardins du Quebec
Quebec, Canada
$246 – – –
1
2

LOGC Hedge Fund Activity: Q3 2022 in Review

39 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in LogicBio Therapeutics, Inc. Common Stock (LOGC) for Q3 2022, worth a combined $513K — down 44% from $917K a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of LOGC and 3 opened new positions — a net loss of 8 holders — while 8 trimmed existing stakes and 4 added.

The largest buyer was Vanguard Group, adding an estimated $73.7K. The largest seller was Baker Bros. Advisors, cutting an estimated $124K.

  • 39 institutional investors held LogicBio Therapeutics, Inc. Common Stock (LOGC) as of Q3 2022, down from 47 in Q2 2022.
  • Funds reported $513K of LogicBio Therapeutics, Inc. Common Stock stock for Q3 2022, down 44% quarter-over-quarter.
  • 3 funds opened new LogicBio Therapeutics, Inc. Common Stock positions in Q3 2022 and 11 closed out, a net change of -8 holders.
  • The largest LogicBio Therapeutics, Inc. Common Stock buyer in Q3 2022 was Vanguard Group, an estimated $73.7K added.
  • The largest LogicBio Therapeutics, Inc. Common Stock seller in Q3 2022 was Baker Bros. Advisors, an estimated $124K sold.

Based on aggregated 13F filings for Q3 2022.